Intermittent preventive therapy for malaria in pregnancy: Is sulfadoxine-pyrimethamine the right drug?

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 2, 2010, Pages 160-162

  Parikh, S ^a   Rosenthal, P J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; FANSIDAR; MEFLOQUINE; PROGUANIL;

AFRICA; ANEMIA; ANTIMALARIAL ACTIVITY; CHEMOPROPHYLAXIS; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; FETUS OUTCOME; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INFANT MORTALITY; INTRAUTERINE GROWTH RETARDATION; MALARIA; MALARIA CONTROL; MATERNAL MORTALITY; MORBIDITY; MORTALITY; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SPONTANEOUS ABORTION; STILLBIRTH; WORLD HEALTH ORGANIZATION;

AFRICA; ANTIMALARIALS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PYRIMETHAMINE; SULFADOXINE;

EID: 75749140207     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.284     Document Type: Short Survey

References (15)

1. Guyatt, H.L. & Snow, R.W. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin. Microbiol. Rev. 17, 760-769 (2004).
2. World Health Organization. WHO Global Malaria Programme: Pregnant Women and Infants http://malaria.who.int/pregnantwomenandinfants.html (2007). Accessed 20 September 2009.
3. White, N.J. Intermittent presumptive treatment for malaria. PLoS Med. 2, e3 (2005).
4. Ter Kuile, F.O., Van Eijk A.M. & Filler, S.J. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297, 2603-2616 (2007).
5. Peters, P.J., Thigpen, M.C., Parise, M.E. & Newman, R.D. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 3, 481-501 (2007).
6. van Eijk, A.M. et al. Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western Kenya who have uncomplicated malaria. J. Infect. Dis. 198, 1550-1553 (2008).
7. Gregson, A. & Plowe, C.V. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57, 117-145 (2005).
8. Dawes, M. & Chowienczyk P.J. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 15, 819-826 (2001).
9. Ward S.A., Sevene E.J., Hastings I.M., Nosten F. & McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis. 7, 136-144 (2007).
10. McGready, R. et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62, 367-371 (2006).
11. Tarning, J. et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53, 3837-3846 (2009).
12. Nyunt, M.M. et al. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin. Pharmacol. Ther. 87, 226-234 (2009).
13. Green, M.D. et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J. Infect. Dis. 196, 1403-1408 (2007).
14. Karunajeewa, H.A. et al. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob. Agents Chemother. 53, 4368-4376 (2009).
15. Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S. & White, N.J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44, 697-704 (2000).